IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis

키워드

참고문헌 (52)

1. Lazaridis KN, "Primary sclerosing cholangitis", N Engl J Med, 375, pp.1161~1170 (2016)
2. Karlsen TH, "Primary sclerosing cholangitis : a comprehensive review", J Hepatol, 67, pp.1298~1323 (2017)
3. Nakazawa T, "Diagnosis of IgG4-related sclerosing cholangitis", World J Gastroenterol, 19, pp.7661~7670 (2013)
4. Tanaka A, "No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan", J Hepatobiliary Pancreat Sci, 24, pp.217~225 (2017)
5. Tanaka A, "Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis", Clin Gastroenterol Hepatol, 15, pp.920~926 (2017)[DOI]
6. Hubers LM, "IgG4-associated cholangitis : a comprehensive review", Clin Rev Allergy Immunol, 48, pp.198~206 (2015)
7. Deshpande V, "Consensus statement on the pathology of IgG4-related disease", Mod Pathol, 25, pp.1181~1192 (2012)
8. Khosroshahi A, "International consensus guidance statement on the management and treatment of IgG4-related disease", Arthritis Rheumatol, 67, pp.1688~1699 (2015)
9. Stone JH, "Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations", Arthritis Rheum, 64, pp.3061~3067 (2012)
10. Umehara H, "A novel clinical entity, IgG4-related disease(IgG4RD) : general concept and details", Mod Rheumatol, 22, pp.1~14 (2012)
11. Umehara H, "Comprehensive diagnostic criteria for IgG4-related disease(IgG4-RD), 2011", Mod Rheumatol, 22, pp.21~30 (2012)
12. Okazaki K, "Current concept and diagnosis of IgG4-related disease in the hepato-bilio-pancreatic system", J Gastroenterol, 48, pp.303~314 (2013)
13. Hamano H, "High serum IgG4 concentrations in patients with sclerosing pancreatitis", N Engl J Med, 344, pp.732~738 (2001)
14. Kamisawa T, "A new clinicopathological entity of IgG4-related autoimmune disease", J Gastroenterol, 38, pp.982~984 (2003)
15. Ohara H, "Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012", J Hepatobiliary Pancreat Sci, 19, pp.536~542 (2012)
16. Beuers U, "IgG4-associated cholangitis:a mimic of PSC", Dig Dis, 33(Suppl 2), pp.176~180 (2015)
17. Doorenspleet ME, "Immunoglobulin G4(+)B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary", pancreatic malignancies, 2016, pp.64, 501~507
18. Ghazale A, "Immunoglobulin G4-associated cholangitis : clinical profile and response to therapy", Gastroenterology, 134, pp.706~715 (2008)
19. Chari ST, "Diagnosis of autoimmune pancreatitis : the Mayo Clinic experience", Clin Gastroenterol Hepatol, 4, pp.1010~1016 (2006)
20. Kanno A, "Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2011", Pancreas, 44, pp.535~539 (2015)
21. Huggett MT, "Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort", Am J Gastroenterol, 109, pp.1675~1683 (2014)
22. de Buy Wenniger LJ, "Exposure to occupational antigens might predispose to IgG4-related disease", Hepatology, 60, pp.1453~1454 (2014)
23. Nakazawa T, "Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification", J Gastroenterol, 47, pp.79~87 (2012)
24. Karlsen TH, "Primary sclerosing cholangitis", Best Pract Res Clin Gastroenterol, 24, pp.655~666 (2010)
25. Hirschfield GM, "Primary sclerosing cholangitis", Lancet, 382, pp.1587~1599 (2013)
26. Giljaca V, "Glucocorticosteroids for primary sclerosing cholangitis", Cochrane Database Syst Rev, (1), pp.CD004036~ (2010)
27. Parkes M, "Do steroids help jaundice caused by primary sclerosing cholangitis", J Clin Gastroenterol, 33, pp.319~322 (2001)
28. Weismüller TJ, "The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy", J Hepatol, 48(Suppl 1), pp.S38~S57 (2008)
29. Worthington J, "Immunopathogenesis of primary sclerosing cholangitis", Clin Rev Allergy Immunol, 28, pp.93~103 (2005)
30. Boberg KM, "Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population", Scand J Gastroenterol, 33, pp.99~103 (1998)
31. Ang TL, "Clinical profile of primary sclerosing cholangitis in Singapore", J Gastroenterol Hepatol, 17, pp.908~913 (2002)
32. Bambha K, "Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community", Gastroenterology, 125, pp.1364~1369 (2003)
33. Kingham JG, "Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom", Gastroenterology, 126, pp.1929~1930 (2004)
34. Kaplan GG, "The burden of large and small duct primary sclerosing cholangitis in adults and children : a population-based analysis", Am J Gastroenterol, 102, pp.1042~1049 (2007)
35. Card TR, "Incidence and mortality of primary sclerosing cholangitis in the UK : a population-based cohort study", J Hepatol, 48, pp.939~944 (2008)
36. Lindkvist B, "Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden", Hepatology, 52, pp.571~577 (2010)
37. Toy E, "The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population", BMC Gastroenterol, 11, pp.83~ (2011)
38. Liang H, "Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom", Medicine (Baltimore), 96, pp.e7116~ (2017)
39. Boonstra K, "Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis : a systematic review", J Hepatol, 56, pp.1181~1188 (2012)
40. Aabakken L, "Role of endoscopy in primary sclerosing cholangitis : European Society of Gastrointestinal Endoscopy(ESGE)and European Association for the Study of the Liver(EASL)clinical guideline", Endoscopy, 49, pp.588~608 (2017)
41. Carolina Palmela, "Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features", Gut and Liver, 12(1), pp.17~29 (2018), 거트앤리버 소화기연관학회협의회
42. Njei B, "Systematic review with meta-analysis : endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis", Aliment Pharmacol Ther, 44, pp.1139~1151 (2016)
43. Lindor KD, "High-dose ursodeoxy cholic acid for the treatment of primary sclerosing cholangitis", Hepatology, 50, pp.808~814 (2009)
44. Chapman R, "Diagnosis and management of primary sclerosing cholangitis", Hepatology, 51, pp.660~678 (2010)
45. Lindor KD, "ACG clinical guideline: primary sclerosing cholangitis", Am J Gastroenterol, 110, pp.646~659 (2015)
46. Lindström L, "Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis", Clin Gastroenterol Hepatol, 11, pp.841~846 (2013)
47. Al Mamari S, "Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis", J Hepatol, 58, pp.329~334 (2013)
48. Rupp C, "Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis", Aliment Pharmacol Ther, 40, pp.1292~1301 (2014)
49. Stanich PP, "Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis", Dig Liver Dis, 43, pp.309~313 (2011)
50. Gluck M, "A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis", J Clin Gastroenterol, 42, pp.1032~1039 (2008)
51. Gotthardt DN, "Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis : outcome after long-term treatment", Gastrointest Endosc, 71, pp.527~534 (2010)
52. Egawa H, "Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry", Am J Transplant, 11, pp.518~527 (2011)

관련 논문AI추천